HVP
REGN icon

Hudson Value Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Hudson Value Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Hold
547
– – 0.09% 95
2026
Q1 		$423K Sell
547
-100
-15% -$76.6K 0.13% 84
2025
Q4 		$499K Sell
647
-112
-15% -$76.1K 0.15% 85
2025
Q3 		$427K Hold
759
– – 0.13% 88
2025
Q2 		$398K Buy
+759
New +$424K 0.14% 89

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Hudson Value Partners's REGN Position: Q2 2026 in Review

Hudson Value Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 547 shares worth $341K. The position accounts for 0.09% of the portfolio, ranked #95.

Hudson Value Partners first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $499K in Q4 2025. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Hudson Value Partners held 547 shares of Regeneron Pharmaceuticals worth $341K as of Q2 2026.
  • Hudson Value Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.09% of Hudson Value Partners's portfolio in Q2 2026, its #95 holding.
  • Hudson Value Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Hudson Value Partners's Regeneron Pharmaceuticals position peaked at $499K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hudson Value Partners's 13F filing for Q2 2026, filed 10 Jul 2026.